Created at	Source	Raw Value	Validated value
June 25, 2024, noon	usa	* intracranial hypertension * hypersensitivity to the active ingredient (propofol or sevoflurane) or to any of the excipients * current volume \< 250ml * history of malignant hyperthermia * liver failure * neutropenia (\<0.5x109) * pregnant or lactating women * have received chemotherapy in the last month since their inclusion in the study	* intracranial hypertension * hypersensitivity to the active ingredient (propofol or sevoflurane) or to any of the excipients * current volume \< 250ml * history of malignant hyperthermia * liver failure * neutropenia (\<0.5x109) * pregnant or lactating women * have received chemotherapy in the last month since their inclusion in the study
Oct. 26, 2020, 11:31 p.m.	usa	- intracranial hypertension - hypersensitivity to the active ingredient (propofol or sevoflurane) or to any of the excipients - current volume < 250ml - history of malignant hyperthermia - liver failure - neutropenia (<0.5x109) - pregnant or lactating women - have received chemotherapy in the last month since their inclusion in the study	- intracranial hypertension - hypersensitivity to the active ingredient (propofol or sevoflurane) or to any of the excipients - current volume < 250ml - history of malignant hyperthermia - liver failure - neutropenia (<0.5x109) - pregnant or lactating women - have received chemotherapy in the last month since their inclusion in the study